Contact

Obora Home About Services Legal Landscape Safety & Evidence Access & Alternatives Contact Evidence, safety, and U.S. policy Ibogaine Treatment Us A careful guide to legal status, emerging research, cardiac safety, and the difficult decisions surrounding ibogaine and addiction treatment. Obora is an independent resource on ibogaine research, safety, and U.S. policy. It does not promote illegal or unsafe access. Starting with context A high-stakes question without simple answers Ibogaine is discussed by people facing drug addiction, families looking for treatment options, and advocates following an evolving addiction crisis. The interest is understandable: early research and personal accounts describe reduced withdrawal symptoms and cravings. But the potential benefits do not remove the serious medical, legal, and ethical considerations. The compound is a potent psychoactive alkaloid derived from Tabernanthe iboga , a shrub with traditional use in Central Africa. Its root bark has also been described as a source of plant medicine with hallucinogenic properties; a general scientific overview is available through the ibogaine reference entry . In the United States, ibogaine is a Schedule I controlled substance under federal law. That means its manufacture, possession, and distribution are illegal outside narrow authorized circumstances, and the Drug Enforcement Administration continues to regulate it as an illicit drug. A state-level shift does not erase federal law or create an approved medical pathway nationwide. 01 / Legal clarity Restriction is the baseline Its legal status in the U.S. is restrictive, even while clinical trials and policy discussions continue to develop. 02 / Safety first Screening is not optional Heart conditions, medication interactions, blood pressure, liver function, and psychiatric history can materially affect patient safety. Mechanism and uncertainty Why ibogaine draws attention in addiction science Ibogaine appears to act across mult

Contact

Keep the conversation grounded.